BioMarin Pharmaceutical — May 1, 2025 release

2025 Full-Year Financial Guidance (in millions, except % and EPS amounts) Item 2025 Guidance Reaffirmed Total Revenues (1) $3,100 to $3,200 Non-GAAP Operating Margin % (2) 32% to 33% Non-GAAP Diluted EPS (2)(3) $4.20 to $4.40 (1)    VOXZOGO contribution to full-year 2025 Total Revenues expected to be in the range of $900 million to $950 million. (2)    Refer to Non-GAAP Information beginning on page 10 of this press release for definitions of Non-GAAP Operating Margin and Non-GAAP Diluted EPS. (3)    Non-GAAP Diluted EPS guidance assumes approximately 200 million Weighted-Average Diluted Shares Outstanding. BioMarin will host a conference call and webcast to discuss first quarter 2025 financial results today, Thursday, May 1, 2025, at 4:30 p.m. ET. This event can be accessed through this link or on the investor section of the BioMarin website at www.biomarin.com. U.S./Canada Dial-in Number: 888-596-4144 Replay Dial-in Number: 800-770-2030 International Dial-in Number: 646-968-2525 Replay International Dial-in Number: 609-800-9909 Conference ID: 4327591 Conference ID: 4327591 About BioMarin BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin pursues treatments that offer new possibilities for patients and families around the world navigating rare or difficult to treat genetic conditions. To learn more, please visit www.biomarin.com.  5 Forward-Looking Statements This press r